Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal

被引:104
作者
Tuttle, R. Michael [2 ]
Brokhin, Matvey [1 ]
Omry, Gal [2 ]
Martorella, Andrew J. [2 ]
Larson, Steven M. [3 ]
Grewal, Ravinder K. [3 ]
Fleisher, Martin
Robbins, Richard J. [4 ]
机构
[1] Geisinger Med Ctr, Div Endocrinol, Danville, PA 17822 USA
[2] Mem Sloan Kettering Canc Ctr, Div Endocrinol, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Div Nucl Med, New York, NY USA
[4] Methodist Hosp, Dept Med, Houston, TX USA
关键词
radioactive iodine; remnant ablation; thyroid cancer; rhTSH; thyrogen;
D O I
10.2967/jnumed.107.049072
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Recent studies have confirmed that radioactive iodine therapy after recombinant human TSH (rhTSH) stimulation effectively ablates the normal thyroid remnant. However, no published study has determined the effectiveness of rhTSH preparations on the important endpoint of disease recurrence. Methods: Disease recurrence was retrospectively assessed a median of 2.5 y after radioiodine remnant ablation (RRA) in 394 consecutive thyroid cancer patients (93% papillary, 71% female, 47 +/- 15 y old [mean +/- SD], median I-131 dose of 3,996 MBq [108 mCi]). Results: Similar rates of clinically evident disease recurrence (4% rhTSH vs. 7% thyroid hormone withdrawal [THW], P = not statistically significant) and residual thyroid bed uptake without other evidence of persistent disease (4% rhTSH vs. 7% THW, P = not statistically significant) were seen in the 320 patients undergoing rhTSH-assisted RRA and the 74 patients prepared for RRA by THW. When the definition of no clinical evidence of disease included a suppressed thyroglobulin level of less than 1 ng/mL and a stimulated thyroglobulin level of less than 2 ng/mL, rhTSH-assisted RRA was associated with significantly higher rates of no clinical evidence of disease (74% rhTSH vs. 55% THW, P = 0.02) and significantly lower rates of persistent disease (19% rhTSH vs. 32% THW, P = 0.02) than was RRA after THW. Patients selected for rhTSH-assisted RRA were older (48 +/- 15 vs. 44 +/- 15 y, P = 0.03) and received a slightly higher administered activity of 1311 (median, 4,033 MBq [109 mCi] vs. 3,811 MBq [103 mCi], P = 0.01) but did not differ with respect to sex, histology, disease stage, or mean time to recurrence (19 +/- 9 mo for rhTSH vs. 20 +/- 16 mo for THW). Conclusion: rhTSH-assisted RRA is associated with rates of clinically evident disease recurrence and persistent uptake in the thyroid bed that are similar to those for traditional THW.
引用
收藏
页码:764 / 770
页数:7
相关论文
共 22 条
  • [1] [Anonymous], 2003, Thyroid Tumors
  • [2] Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation
    Barbaro, D
    Boni, G
    Meucci, G
    Simi, U
    Lapi, P
    Orsini, P
    Pasquini, C
    Piazza, F
    Caciagli, M
    Mariani, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (09) : 4110 - 4115
  • [3] Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy
    Dow, KH
    Ferrell, BR
    Anello, C
    [J]. THYROID, 1997, 7 (04) : 613 - 619
  • [4] A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer
    Haugen, BR
    Pacini, F
    Reiners, C
    Schlumberger, M
    Ladenson, PW
    Sherman, SI
    Cooper, DS
    Graham, KE
    Braverman, LE
    Skarulis, MC
    Davies, TF
    DeGroot, LJ
    Mazzaferri, EL
    Daniels, GH
    Ross, DS
    Luster, M
    Samuels, MH
    Becker, DV
    Maxon, HR
    Cavalieri, RR
    Spencer, CA
    McEllin, K
    Weintraub, BD
    Ridgway, EC
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) : 3877 - 3885
  • [5] Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma
    Ladenson, PW
    Braverman, LE
    Mazzaferri, EL
    BruckerDavis, F
    Cooper, DS
    Garber, JR
    Wondisford, FE
    Davies, TF
    DeGroot, LJ
    Daniels, GH
    Ross, DS
    Weintraub, BD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (13) : 888 - 896
  • [6] Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: A one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration
    Luster, M
    Felbinger, R
    Dietlein, M
    Reiners, C
    [J]. THYROID, 2005, 15 (10) : 1147 - 1155
  • [7] rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review
    Luster, M
    Lippi, F
    Jarzab, B
    Perros, P
    Lassmann, M
    Reiners, C
    Pacini, F
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (01) : 49 - 64
  • [8] A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma
    Mazzaferri, EL
    Robbins, RJ
    Spencer, CA
    Braverman, LE
    Pacini, F
    Wartofsky, L
    Haugen, BR
    Sherman, SI
    Cooper, DS
    Braunstein, GD
    Lee, S
    Davies, TF
    Arafah, BM
    Ladenson, PW
    Pinchera, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04) : 1433 - 1441
  • [9] Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study
    Pacini, F
    Ladenson, PW
    Schlumberger, M
    Driedger, A
    Luster, M
    Kloos, RT
    Sherman, S
    Haugen, B
    Corone, C
    Molinaro, E
    Elisei, R
    Ceccarelli, C
    Pinchera, A
    Wahl, RL
    Leboulleux, S
    Ricard, M
    Yoo, J
    Busaidy, NL
    Delpassand, E
    Hanscheid, H
    Felbinger, R
    Lassmann, M
    Reiners, C
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (03) : 926 - 932
  • [10] Ablation of thyroid residues with 30 mCi 131I:: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal
    Pacini, F
    Molinaro, E
    Castagna, MG
    Lippi, F
    Ceccarelli, C
    Agate, L
    Elisei, R
    Pinchera, A
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (09) : 4063 - 4068